CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that it will host an Analyst and Investor Day on Tuesday, June 27, 2017. The event is scheduled to take place from 8:00-11:00 AM Eastern Time in New York City.
The agenda will include a review of the Company's HIF programs as well as presentations by the following guest speakers:
- Geoffrey A. Block, M.D., Director of Research, Denver Nephrology
- Cormac Taylor B.Sc., Ph.D., Professor of Cellular Physiology, University College Dublin, School of Medicine
A live audio webcast of the event will be available on the Company's website at http://ir.akebia.com/events.cfm. To ensure a timely connection, users should register at least 15 minutes prior to the scheduled start. An archived replay will be available for 90 days.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor biology. Akebia's lead product candidate, vadadustat, is an oral, investigational therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. Akebia's global Phase 3 program for vadadustat, which includes the PRO2TECT studies for non-dialysis patients with anemia secondary to chronic kidney disease and the INNO2VATE studies for dialysis-dependent patients, is currently ongoing. For more information, please visit our website at www.akebia.com.